Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
07:30am, Friday, 08'th Nov 2024
mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA fol
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
07:30am, Friday, 08'th Nov 2024
New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA , Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeu
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
02:35pm, Thursday, 07'th Nov 2024
MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.
Moderna Stock Rises on Surprise Q3 Profit
12:16pm, Thursday, 07'th Nov 2024
Moderna (MRNA) reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs.
Moderna (MRNA) Q3 2024 Earnings Call Transcript
12:08pm, Thursday, 07'th Nov 2024
Call Start: 08:00 January 1, 0000 9:00 AM ET Moderna Inc. (NASDAQ:MRNA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 am ET Company Participants Stéphane Bancel - Chief Executive Officer St
2025 will be 'fairly challenging' for Moderna: Analyst
11:57am, Thursday, 07'th Nov 2024
Moderna (MRNA) shares are getting a boost in Thursday's pre-market trading as the pharmaceutical giant reported an unexpected profit in its third quarter. The company posted $1.86 billion in revenue a
Initial Claims Increased Slightly More Than Expected
11:45am, Thursday, 07'th Nov 2024
The other long-expected big news item for market participants this week comes this afternoon, with the Federal Open Market Committee (FOMC) determining a new Fed funds rate. This follows the “red wa
Ahead of Fed Decision, Big Earnings Wins for Forgotten Names
11:10am, Thursday, 07'th Nov 2024
The long-expected big news item for market participants this afternoon is the Fed interest rate move.
LYFT Drives Big Rally, ELF's Earnings Makeover, MRNA Bounces Back
10:04am, Thursday, 07'th Nov 2024
Lyft Inc. (LYFT) is racing to catch up to Uber Technologies (UBER) after an earnings beat and guidance raise thrust shares to the upside. e.l.f. Beauty (ELF) covered blemishes from its previous report
Buy, Sell, Or Hold MRNA Stock?
09:35am, Thursday, 07'th Nov 2024
The stock price of Moderna has seen a sharp 48% fall this year. From its lows of around $50, it is expected to see a rebound after posting a solid Q3 beat.
Moderna Q3 Revenue Beats On Updated COVID-19 Vaccine, Slashes Expenses For 2024
09:06am, Thursday, 07'th Nov 2024
On Thursday, Moderna Inc MRNA stock is trading higher after the company reported better-than-expected third-quarter sales.
Moderna (MRNA) Q3 Earnings and Revenues Surpass Estimates
08:40am, Thursday, 07'th Nov 2024
Moderna (MRNA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $1.89 per share. This compares to loss of $1.39 per share a year ago.
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
08:04am, Thursday, 07'th Nov 2024
Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, impact of President-elect Trump's election victory, status of the company's cancer vaccine, and more
Moderna's stock pops after biotech ekes out profit and revenue beats by a wide margin
07:15am, Thursday, 07'th Nov 2024
Moderna Inc.'s stock jumped 5% early Thursday, after the company's third-quarter earnings showed an unexpected profit and revenue that beat estimates by a wide margin.
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
06:34am, Thursday, 07'th Nov 2024
Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected.
